<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811018</url>
  </required_header>
  <id_info>
    <org_study_id>B1321007</org_study_id>
    <secondary_id>FPH03</secondary_id>
    <nct_id>NCT00811018</nct_id>
  </id_info>
  <brief_title>A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension</brief_title>
  <acronym>STRIDE-3</acronym>
  <official_title>A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily
      by subjects with PAH until sitaxsentan, in a particular country or region, is commercially
      available for the treatment of PAH or the study is closed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label extension
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This trial was prematurely terminated on Dec 9 2010 due to safety concerns, specifically
    emerging evidence of hepatic injury.
  </why_stopped>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 up to 82 months</time_frame>
    <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Who Experience an Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Value Greater Than (&gt;) 3.0 Times (x) the Upper Limit of Normal Range (ULN)</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
    <description>ALT and AST data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Who Experience an ALT and AST Value &gt; 3.0 x ULN</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
    <description>ALT and AST data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Total Bilirubin &gt; 1.5 x ULN</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
    <description>Total builirubin data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Laboratory Test Abnormalities (Hematology)</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
    <description>Hematology data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Laboratory Test Abnormalities (Chemistry)</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
    <description>Chemistry data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Laboratory Test Abnormalities (Urinalysis)</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
    <description>Urinalysis data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Anticoagulant Use</measure>
    <time_frame>Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months</time_frame>
    <description>Participants with anticoagulant use before first dose or participants with anticoagulant use from first dose of sitaxsentan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Elevated International Normalize Ratio (INR)</measure>
    <time_frame>Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months</time_frame>
    <description>Elevated INR in participants who took warfarin, warfarin derivatives, other anticoagulant and no anticoagulants. Elevated INR defined as &gt; 3.5. Percentage calculated using number of participants with INR data as the denominator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Electrocardiography (ECG) Results of Potential Clinical Importance</measure>
    <time_frame>Weeks 28,60,72,84,96,104, Transition Visit up to 82 months</time_frame>
    <description>Standard 12-lead ECG results determined to be of potential clinical importance according to investigator clinical judgement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Vital Sign Results of Potential Clinical Importance</measure>
    <time_frame>Day 1, Weeks 28,60,72,84,96,104, Transition visit, every 6 months Post Transition, up to 82 months</time_frame>
    <description>Vital signs include sitting blood pressure, respiration rate, heart rate and temperature. Potential clinical importance determined according to investigator clinical judgement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Abnormal Prothrombin Time (PT)</measure>
    <time_frame>Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months</time_frame>
    <description>PT data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Abnormal Partial Thromboplastin Time (PTT)</measure>
    <time_frame>Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months</time_frame>
    <description>PTT data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1192</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Sitaxsentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitaxsentan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitaxsentan</intervention_name>
    <description>Sitaxsentan 100 mg tablets once daily</description>
    <arm_group_label>Sitaxsentan</arm_group_label>
    <other_name>Sitaxentan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Pulmonary Arterial Hypertension (PAH) confirmed by cardiac
             catheterization.

          -  Current diagnosis of WHO group 1 PAH with functional class 2, 3, or 4 symptoms.

        Exclusion Criteria:

          -  Has portal hypertension or chronic liver disease.

          -  Has history of left sided heart disease or significant cardiac disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torrence</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112-1393</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903-0019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1416ASA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1039AAO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chermside Q</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chermside</city>
        <zip>QLD 4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>B - 3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30380-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clamart Cedex</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>GRENOBLE Cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tel-Hashomer, Ramat Gan</city>
        <zip>52601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>CP</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tlalpan</city>
        <state>DF</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>N.l.</state>
        <zip>64360</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Papworth Everard</city>
        <state>Cambridgeshire</state>
        <zip>CB3 8RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1321007&amp;StudyName=A%20Long-Term%2C%20Open-Label%20Study%20to%20Evaluate%20the%20Safety%20of%20Sitaxsentan%20Sodium%20Treatment%20in%20Patients%20with%20Pulmonary%20Arterial%20Hypertension</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <results_first_submitted>March 29, 2012</results_first_submitted>
  <results_first_submitted_qc>March 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 24, 2012</results_first_posted>
  <last_update_submitted>March 29, 2012</last_update_submitted>
  <last_update_submitted_qc>March 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-label study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitaxsentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from studies FPH02/FPH02-X (STRIDE 2/STRIDE 2 Extension [NCT00080457, NCT00593905]), FPH04 (STRIDE 4), FPH06 (STRIDE 6) or were naive to sitaxsentan sodium.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitaxsentan</title>
          <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1192"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="968"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Additional Chronic Treatment</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ALT/AST &gt;3x UNL, Bilirubin &gt;2xUNL</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ALT/AST &gt;5x Upper Limit of Normal (ULN)</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="450"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WHO FC deterioration and 6MWD decrease</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitaxsentan</title>
          <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1192"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>less than (&lt;) 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>greater than or equal to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product were reported.</description>
        <time_frame>Day 1 up to 82 months</time_frame>
        <population>Safety Population: all enrolled participants who took at least one dose of sitaxsentan 100 mg during the study</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product were reported.</description>
          <population>Safety Population: all enrolled participants who took at least one dose of sitaxsentan 100 mg during the study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Experience an Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Value Greater Than (&gt;) 3.0 Times (x) the Upper Limit of Normal Range (ULN)</title>
        <description>ALT and AST data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
        <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Experience an Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Value Greater Than (&gt;) 3.0 Times (x) the Upper Limit of Normal Range (ULN)</title>
          <description>ALT and AST data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
          <population>Safety Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt; 3 x ULN and less than or equal to (&lt;=) 5x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 5 x ULN and &lt;= 8 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 8 x ULN and &lt;= 10 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 10 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Experience an ALT and AST Value &gt; 3.0 x ULN</title>
        <description>ALT and AST data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
        <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Experience an ALT and AST Value &gt; 3.0 x ULN</title>
          <description>ALT and AST data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
          <population>Safety Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt; 3 x ULN and &lt;= 5 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 5 x ULN and &lt;= 8 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 8 x ULN and &lt;= 10 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 10 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Total Bilirubin &gt; 1.5 x ULN</title>
        <description>Total builirubin data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
        <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Total Bilirubin &gt; 1.5 x ULN</title>
          <description>Total builirubin data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
          <population>Safety Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= 1.5 x ULN and &lt;2 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 2 x ULN and &lt; 3x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 3x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Laboratory Test Abnormalities (Hematology)</title>
        <description>Hematology data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
        <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
        <population>Safety Population; N=number of participants with normal observation at baseline; n=number of participants with normal baseline and an abnormality meeting specific criteria for the specific lab</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Laboratory Test Abnormalities (Hematology)</title>
          <description>Hematology data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
          <population>Safety Population; N=number of participants with normal observation at baseline; n=number of participants with normal baseline and an abnormality meeting specific criteria for the specific lab</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophiles (n=814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophiles % (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (n=785)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit (n=537)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (n=573)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (n=737)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscular Hemoglobin (n=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscular Hemoglobin Concentration (n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscular Volume (n=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (n=766)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophiles (n=728)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets Count (n=719)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cells (n=542)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells (n=730)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Laboratory Test Abnormalities (Chemistry)</title>
        <description>Chemistry data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
        <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
        <population>Safety Population; N=number of participants with normal observation at baseline; n=number of participants with normal baseline and an abnormality meeting specific criteria for the specific lab</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Laboratory Test Abnormalities (Chemistry)</title>
          <description>Chemistry data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
          <population>Safety Population; N=number of participants with normal observation at baseline; n=number of participants with normal baseline and an abnormality meeting specific criteria for the specific lab</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="839"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin (n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase (n=593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (n=839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (n=814)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (n=540)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen (BUN) (n=615)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (n=819)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride (n=804)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (n=808)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma glutamyltransferase (GGT) (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (n=674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose-fasting (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect Bilirubin (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus (n=740)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (n=749)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (n=811)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin (n=726)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein (n=738)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid (n=415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Laboratory Test Abnormalities (Urinalysis)</title>
        <description>Urinalysis data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
        <time_frame>Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months</time_frame>
        <population>Safety Population; N=number of participants with normal observation at baseline; n=number of participants with normal baseline and an abnormality meeting specific criteria for the specific lab</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Laboratory Test Abnormalities (Urinalysis)</title>
          <description>Urinalysis data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
          <population>Safety Population; N=number of participants with normal observation at baseline; n=number of participants with normal baseline and an abnormality meeting specific criteria for the specific lab</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="789"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PH (n=789)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specific Gravity (n=787)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Anticoagulant Use</title>
        <description>Participants with anticoagulant use before first dose or participants with anticoagulant use from first dose of sitaxsentan.</description>
        <time_frame>Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anticoagulant Use</title>
          <description>Participants with anticoagulant use before first dose or participants with anticoagulant use from first dose of sitaxsentan.</description>
          <population>Safety Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Warfarin before first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warfarin Derivatives before first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Anticoagulants before first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warfarin from first dose/data cut off</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warfarin Derivatives from first dose/data cut off</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Anticoagulants from first dose/data cut off</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Elevated International Normalize Ratio (INR)</title>
        <description>Elevated INR in participants who took warfarin, warfarin derivatives, other anticoagulant and no anticoagulants. Elevated INR defined as &gt; 3.5. Percentage calculated using number of participants with INR data as the denominator.</description>
        <time_frame>Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated International Normalize Ratio (INR)</title>
          <description>Elevated INR in participants who took warfarin, warfarin derivatives, other anticoagulant and no anticoagulants. Elevated INR defined as &gt; 3.5. Percentage calculated using number of participants with INR data as the denominator.</description>
          <population>Safety Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>INR &lt;= 3.5; warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt;3.5 and &lt;=5; warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt;5 and &lt;=9; warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt; 9; warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &lt;=3.5; warfarin derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt;3.5 and &lt;=5; warfarin derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt;5 and &lt;=9; warfarin derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt;9; warfarin derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &lt;=3.5; other anticoagulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt;3.5 and &lt;=5; other anticoagulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt;5 and &lt;= 9; other anticoagulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &lt;=3.5; no anticoagulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt;3.5 and &lt;= 5; no anticoagulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt;5 and &lt;=9; no anticoagulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR &gt;9; no anticoagulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Electrocardiography (ECG) Results of Potential Clinical Importance</title>
        <description>Standard 12-lead ECG results determined to be of potential clinical importance according to investigator clinical judgement.</description>
        <time_frame>Weeks 28,60,72,84,96,104, Transition Visit up to 82 months</time_frame>
        <population>Data not summarized, study terminated early</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Electrocardiography (ECG) Results of Potential Clinical Importance</title>
          <description>Standard 12-lead ECG results determined to be of potential clinical importance according to investigator clinical judgement.</description>
          <population>Data not summarized, study terminated early</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Vital Sign Results of Potential Clinical Importance</title>
        <description>Vital signs include sitting blood pressure, respiration rate, heart rate and temperature. Potential clinical importance determined according to investigator clinical judgement.</description>
        <time_frame>Day 1, Weeks 28,60,72,84,96,104, Transition visit, every 6 months Post Transition, up to 82 months</time_frame>
        <population>Data not summarized, study terminated early</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Vital Sign Results of Potential Clinical Importance</title>
          <description>Vital signs include sitting blood pressure, respiration rate, heart rate and temperature. Potential clinical importance determined according to investigator clinical judgement.</description>
          <population>Data not summarized, study terminated early</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Abnormal Prothrombin Time (PT)</title>
        <description>PT data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
        <time_frame>Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months</time_frame>
        <population>Data not summarized, study terminated early</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Abnormal Prothrombin Time (PT)</title>
          <description>PT data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
          <population>Data not summarized, study terminated early</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Abnormal Partial Thromboplastin Time (PTT)</title>
        <description>PTT data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
        <time_frame>Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months</time_frame>
        <population>Data not summarized, study terminated early</population>
        <group_list>
          <group group_id="O1">
            <title>Sitaxsentan</title>
            <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Abnormal Partial Thromboplastin Time (PTT)</title>
          <description>PTT data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis.</description>
          <population>Data not summarized, study terminated early</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitaxsentan</title>
          <description>All participants received sitaxsentan 100 milligrams (mg) orally once daily beginning on Study Day 1 to termination from study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="586" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cor pulmonale acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Low cardiac output syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Right atrial dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Oesophageal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Therapeutic response unexpected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gallbladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Dermo-hypodermitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Peritonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pyometra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Collapse of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gastroenteritis radiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Angiogram</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Apnoea test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Aspiration bronchial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Biopsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Biopsy lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bleeding time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bronchoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac normal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Diagnostic procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>ECG signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Echocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Oxygen consumption increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Physical examination</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pregnancy test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Volume blood increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Electrolyte depletion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hyperosmolar state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Articular calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>CREST syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Inguinal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Systemic sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ureteral neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cerebral hypoperfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Missed labour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ureteric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ovarian mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Reproductive tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pulmonary veno-occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anticoagulant therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Atrial septal defect repair</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Balloon atrial septostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Catheter placement</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Central venous catheter removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Cholelithotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Drug therapy</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Endarterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Endotracheal intubation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Eye operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Foot amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Heart and lung transplant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hernia diaphragmatic repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Infusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Intraocular lens implant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lens implant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lung transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Lymphadenectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Office visit</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Packed red blood cell transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pain management</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Phlebectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Prophylaxis against gastrointestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Routine health maintenance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Spinal cord operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Therapy cessation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Therapy regimen changed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Transurethral bladder resection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Uterine dilation and curettage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Varicose vein operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Vascular bypass graft</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Wound treatment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Raynaud’s phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1069" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="224" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="287" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="306" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="294" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="1192"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Mean and dispersion for clinical abnormalities were intended to be reported but due to early termination of study (09-Dec-2010) only number and percent of participants are available.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

